Variables | Univariate model | aMultivariate model | ||
---|---|---|---|---|
HRÂ (95%Â CI) | Model I Time-invariant without recurrence aHRÂ (95%Â CI) | Model II Time-invariant with recurrence aHRÂ (95%Â CI) | Model III Time-varying with recurrence aHRÂ (95%Â CI) | |
Time-dependent variables | ||||
 Recurrence type | ||||
  No | 1.00 |  |  | 1.00 |
  Early recurrence (< 1 year) | 9.44 (4.98–17.9) |  |  | 6.62 (3.79–11.6) |
  Late recurrence (> 1 year) | 6.46 (3.17–13.2) |  |  | 3.75 (1.99–7.08) |
Time-independent variables | ||||
 Recurrence type | ||||
  No | 1.00 |  | 1.00 |  |
  Early (< 1 year) | 4.51 (2.42–8.39) |  | 3.09 (2.03–4.71) |  |
  Late (> 1 year) | 1.73 (0.91–3.28) |  |  |  |
 Host-related factors | ||||
  Age > 65 years | 1.64 (1.09–2.48) |  | 1.43 (0.92–2.21) | 1.55 (1.01–2.36) |
  Male | 1.23 (0.81–1.86) |  |  |  |
  AST > 80 IU/L | 1.30 (0.80–2.11) |  |  |  |
  ALT > 80 IU/L | 0.99 (0.60–1.63) |  |  |  |
  Total bilirubin > 1.5 mg/dL | 1.93 (1.00–3.72) |  |  |  |
  Prothrombin time (INR) > 1.3 | 1.86 (0.86–4.04) |  |  |  |
  Albumin <3.0 mg/dL | 2.38 (1.20–4.75) |  |  |  |
  Child-Pugh score B (vs A) | 1.63 (0.75–3.53) |  |  |  |
  CSPH | 2.31 (1.50–3.56) | 1.53 (0.93–2.52) | 1.71 (1.04–2.82) | 1.97 (1.26–3.08) |
  Creatinine > 1.5 mg/dL | 2.04 (0.98–4.22) | 1.93 (0.92–4.02) | 1.89 (0.90–3.97) |  |
  Diabetes | 1.23 (0.79–1.90) |  |  |  |
  ALBI grade 2 or 3 (vs 1) | 1.91 (1.02–3.59) |  |  |  |
  FIB-4 index > 3.25 | 2.50 (1.63–3.84) | 2.02 (1.23–3.31) | 1.83 (1.12–3.01) |  |
 Tumor characteristics | ||||
  Size > 3 cm | 1.02 (0.67–1.54) |  |  |  |
  Multinodularity | 1.18 (0.75–1.84) |  |  |  |
  AFP > 20 ng/mL | 1.20 (0.79–1.81) |  |  |  |
  BCLC stage A (vs 0) | 1.94 (1.03–3.65) | 1.88 (1.00–3.55) |  |  |
 Histopathological findings | ||||
  Edmonson grade III & IV | 1.35 (0.76–2.40) |  |  |  |
  Ishak fibrosis score 4–6 | 1.24 (0.79–1.96) |  |  |  |
 Viral factors | ||||
  HBV | 5.23 (2.86–9.57) |  |  |  |
  HCV | 5.36 (2.96–9.70) |  |  |  |
  HBV and HCV | 10.3 (3.77–28.1) |  |  |  |
 Treatment modality |  |  |  |  |
  RFA-TACE (vs. Surgery) | 1.25 (0.82–1.91) |  |  |  |
Model selection | ||||
 -2 log likelihood ratio |  | 871.9 | 847.7 | 834.5 |
 AIC |  | 879.9 | 857.7 | 842.5 |